ABSTRACT
Until recently, the treatment of sarcoidosis was determined by empiric selec-
tion of drugs based on observational studies and expected drug toxicities. With improved understanding of the processes involved in granuloma forma-
tion, a framework for designing management strategies based on known
pathogenic mechanisms in sarcoidosis is now possible to consider.
